Lifelong genetically lowered sclerostin and risk of cardiovascular disease.

Bovijn, J.; Krebs, K.; Chen, C.-Y.; Boxall, R.; Censin, J. C.; Ferreira, T.; Pulit, S. L.; Glastonbury, C. A.; Laber, S.; Millwood, I. Y.; Lin, K.; Li, L.; Chen, Z.; Milani, L.; Walters, R. G.; Mägi, R.; Neale, B. M.; Lindgren, C. M.; Holmes, M. V.

doi:10.1101/531004

bioRxiv · 10.1101/531004

Lifelong genetically lowered sclerostin and risk of cardiovascular disease.

Bovijn, J.·Krebs, K.·Chen, C.-Y.·Boxall, R.·Censin, J. C.·Ferreira, T.·Pulit, S. L.·Glastonbury, C. A.·Laber, S.·Millwood, I. Y.·Lin, K.·Li, L.·Chen, Z.·Milani, L.·Walters, R. G.·Mägi, R.·Neale, B. M.·Lindgren, C. M.·Holmes, M. V.

View original source ↗Export metadata ↓

Abstract

BackgroundInhibition of sclerostin is a novel therapeutic approach to lowering fracture risk. However, phase III randomised controlled trials (RCTs) of romosozumab, a monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular events. MethodsWe used two independent genetic variants (rs7209826 and rs188810925) in SOST (encoding sclerostin) associated with bone mineral density (BMD) as proxies for therapeutic inhibition of sclerostin. We estimated the effects on risk of osteoporosis, fracture, coronary heart disease (CHD) and a further 22 cardiometabolic risk factors and diseases, by combining data from up to 478,967 participants of European ancestry from three prospective cohorts and up to 1,030,836 participants from nine GWAS consortia. In addition, we performed meta-analyses of cardiovascular outcome data from phase III RCTs of romosozumab. ResultsMeta-analysis of RCTs identified a higher risk of cardiac ischemic events in patients randomised to romosozumab (25 events among 4,298 individuals; odds ratio [OR] 2{middle dot}98; 95% confidence interval [CI], 1{middle dot}18 to 7{middle dot}55; P=0{middle dot}017). Scaled to the equivalent dose of romosozumab (210mg/month; 0{middle dot}09 g/cm2 higher BMD), the SOST variants associated with lower risk of fracture (OR, 0{middle dot}59; 95% CI, 0{middle dot}54-0{middle dot}66; P= 1{middle dot}4x10-24), and osteoporosis (OR, 0{middle dot}43; 95% CI, 0{middle dot}36-0{middle dot}52; P=2{middle dot}4x10-18). The SOST variants associated with higher risk of myocardial infarction and/or coronary revascularisation (69,649 cases; OR, 1{middle dot}18; 95% CI, 1{middle dot}06-1{middle dot}32; P=0{middle dot}003) and type 2 diabetes (OR 1{middle dot}15; 95% CI, 1{middle dot}05-1{middle dot}27; P=0{middle dot}003), higher systolic blood pressure (1{middle dot}3mmHg; 95% CI 0{middle dot}8-1{middle dot}9; P=5{middle dot}9x10-6) and waist-to-hip-ratio adjusted for BMI (0{middle dot}05 SDs; 95% CI, 0{middle dot}02 to 0{middle dot}08; P=8{middle dot}5x10-4). ConclusionsGenetically and therapeutically lowered sclerostin leads to higher risk of cardiovascular events. Rigorous evaluation of the cardiovascular safety of romosozumab and other sclerostin inhibitors is warranted.

Explore related subjects

genetics Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Bovijn, J., Krebs, K., Chen, C.-Y., Boxall, R., Censin, J. C., Ferreira, T., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., Lin, K., Li, L., Chen, Z., Milani, L., Walters, R. G., Mägi, R., Neale, B. M., Lindgren, C. M., Holmes, M. V.. 2019-02-01. Lifelong genetically lowered sclerostin and risk of cardiovascular disease.. https://doi.org/10.1101/531004

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Deep transcriptomic analysis of molecular mediators of complex traits in heterogeneous stock (HS) rats

Rats are a powerful model organism for genome-wide association studies (GWAS) of physiological and behavioral traits. Heterogeneous Stock (HS) rats, which were created by intercrossing 8 inbred rat strains, are heavily used for this purpose because of their genetic diversity and accumulated recombinations due to over 100 generations of outbreeding, which improves mapping precision. However, functional genomics resources for post-GWAS interpretation of genomic findings have been limited. We processed 3,160 RNA-seq samples, 1,932 of which were previously unpublished, from 13 tissues as part of RatGTEx. We used Pantry to quantify six modalities of transcriptome regulation (expression, isoform ratio, intron excision ratio, alternative transcription start site (TSS), alternative poly(A), and RNA stability) in each sample, which allowed us to identify 144,876 independent quantitative trait loci (QTL) for 22,599 genes. We performed a transcriptome-wide association study (TWAS) with 19,796 unique genes across tissues and transcriptional modalities and 308 traits collected from 14 studies using FUSION, which identified 7,473 significant gene-trait associations. This work presents a significant expansion of the RatGTEx resource in terms of samples, modes of transcriptome regulation, and genetic analyses. Our findings provide molecular evidence for the involvement of specific genes in mediating GWAS signals through a range of transcriptome regulatory mechanisms. These gene-to-phenotype relationships can be easily applied to genetic analyses in humans and other species. Further experiments can use this evidence to confirm these molecular mediators and target them for the treatment of behavioral and physiological traits and disorders. To facilitate use of these results, we have updated results on RatGTEx.org and provided a new interactive TWAS web portal (twas.ratgtex.org).

genetics↗

bioRxiv2026

Genomic and Epigenomic Relationships Capture Different Patterns of Genotype-by-Environment Interaction in Grapevine Clones

Genotype-by-environment interaction (GEI) challenges selection in clonally propagated perennial crops by reducing the consistency of clone performance across years. In perennial crops, both genetic and epigenetic variation are likely to contribute to complex trait variation among clones. However, the extent to which each molecular source contribute to GEI remains poorly understood. Here, we used UMR-seq, an assay that recovers SNPs and unmethylated-region (UMR; DNA methylation) profiles from a single library, to generate paired genomic and epigenomic profiles for 206 Riesling (Vitis vinifera L.) clones phenotyped for yield and juice quality traits across nine growing seasons. We then partitioned the contribution of each omic layer to clonal variation and GEI, and examined the genomic distribution of their effects. In models without explicit GEI, environmental and residual effects were the largest source of phenotypic variance and the clonal main effect was modest. Genomic relationships accounted for most of the clonal variance in four of five traits, and adding an epigenomic relationship matrix (ERM) to the genomic relationship matrix (GRM) had little effect. In contrast, when GEI effects were modelled using factor-analytic covariance structures, the epigenomic layer captured a substantial proportion of GEI variance and exceeded the genomic contribution in four of five traits. The two omic layers differed not only in the amount of GEI captured, but also in the pattern of clone re-ranking across years. When back-solved effects were aggregated into genomic windows, the largest genomic and epigenomic effects tended to fall in different regions, with overlap no greater than expected by chance. Together, these results show that genomic and epigenomic relationships capture complementary components of year-to-year variation in clone performance, with the epigenomic contribution expressed primarily through GEI. These findings provide a basis for investigating the molecular drivers of GEI and for testing whether genomic and epigenomic information can inform selection for stable clonal performance across variable environments.

genetics↗

bioRxiv2026

Transportability of mouse gene knockout models to human complex phenotypes

Mouse gene knockout studies are a valuable resource for understanding human gene function and the mechanisms underlying disease. However, translating insights to humans requires causal similarities between mouse and human phenotypes. A mouse model is transportable if gene perturbations that impact the mouse phenotype also affect (in orthologous genes) the corresponding human phenotype of interest, with consistent directionality. To assess the transportability of mouse models to human complex traits we combined laboratory mouse gene perturbation data from the high-throughput International Mouse Phenotyping Consortium with predicted loss-of-function data from the UK Biobank within the Gene Perturbation Analysis for Transportability (GPAT) framework. Applying GPAT to 30 matched mouse-human phenotype pairs, we found evidence of transportability for 12 mouse phenotypes including biochemical (e.g. total cholesterol), cellular (e.g. lymphocyte counts) and anthropometric (e.g. length/height) phenotypes. In contrast, there was limited evidence for others such as fat mass and body mass index in the context of the murine experimental conditions. We also found some evidence of transportability of mouse glucose measurements to diabetes mellitus in humans. Genome-wide perturbation effects on matched phenotypes were on average positively correlated between mice and humans (meta-analysis GPAT P = 2.3x10-27). However, the degree of correlation was generally modest and heterogeneous across phenotypes with some gene perturbations strongly associated in both species in opposite directions. Our framework illustrates how perturbation data can be used to quantitatively validate experimental models for understanding human disease aetiology and highlights the need for a range of orthogonal model systems, which may include challenges and perturbations to the mouse knockouts, to interrogate the mechanistic basis of human genetic associations.

genetics↗